the aid library

LIST OPTIONS

Filter

6934

Sort by:

Direction:

Download (166)

View PDF (226)

Improving Mental Well-Being and Productivity of Small-Medium Entrepreneurs in Fragile, Conflict and Violence Affected Areas

Saraf, P.; T. Rahman; M. Gallardo, et al. (2018) C1

This literature review summarizes the link between psychological well-being and entrepreneurial outcomes for small and medium-size enterprises in fragile, conflict, and violence–affected contexts. It identifies potentially promising, scalable psychosocial training interventions, based on cognitive... more

Download (735)

View PDF (2145)

Nepal: National List of Essential Medicines, 2021
recommended

World Health Organisation (WHO) (2021) C_WHO

6th edition, The NLEM 2021 contains 398 drugs molecules in different therapeutic categories.

Download (129)

View PDF (131)

Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews. Rapid Review

Pan American Health Organisation PAHO (2020) C_WHO

As of 31 October 2020 This is the tenth edition of this summary of rapid systematic reviews, which includes the results of a rapid systematic review of currently available literature. More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. I... more

Download (160)

View PDF (197)

COVID-19 clinical care pathway (‎CARE)‎: confirm, assess, respond, evaluate

World Health Organization WHO (2022) CC

The COVID-19 CARE pathway is a living tool to support health care workers visualize the current clinical and therapeutic recommendations to be considered in the care planning for patients with COVID-19. The COVID-19 CARE pathway is aligned with the eighth version of the WHO Therapeutics and COVID... more

Download (227)

View PDF (166)

WHO standard acupuncture point locations in the Western Pacific region

World Health Organization (WHO) (2009) C_WHO

Acupuncture has been practised for more than 2500 years in the Western Pacific Region and has become a global therapeutic method in recent decades. However, it was reportedthat acupuncturists differed by up to 25% in the acupuncture points they used, raising doubts and uncertainty regarding the effi... more

Download (135)

View PDF (181)

Global initiative for childhood cancer

World Health Organization WHO (2020) C_WHO

Childhood cancer is curable for the vast majority of children when essential diagnostic, therapeutic and supportive care services are accessible. However, profound inequalities in outcomes exist within and between countries with as few as 20% or 30% of children living in low- and middle-income count... more

Download (89)

View PDF (332)

Chromoblastomycosis: a neglected tropical disease

Scientific Electronic Library Online SciELO (2015) CC

Chromoblastomycosis (CMB) is a chronic fungal infection of the skin and the subcutaneous tissue caused by a transcutaneous traumatic inoculation of a specific group of dematiaceous fungi occurring mainly in tropical and subtropical zones worldwide. If not diagnosed at early stages, patients with CBM... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (19)

View PDF (23)

Men and HIV: evidence-based approaches and interventions

World Health Organization WHO (2023) C_WHO

Men experience increased risk of morbidity and mortality across all ten major contributors to poor health and continue to lag behind women regarding HIV services and other health outcomes. Globally, men now account for the majority of new HIV infections. In 2022, only 72% of men living with HIV (age... more

Download (21)

View PDF (19)

Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease

Abola, M. T. B.; Golledge, J.; Miyata, T. et al. Journal of Atherosclerosis and Thrombosis (2020) CC

Peripheral artery disease (PAD) is the most underdiagnosed, underestimated and undertreated of the atherosclerotic vascular diseases despite its poor prognosis. There may be racial or contextual differences in the Asia-Pacific region as to epidemiology, availability of diagnostic and therapeutic mod... more

Download (14)

View PDF (12)

Primary and Secondary Prevention of Ischemic Stroke

Paciaroni, M.; Bogousslavsky, J. European Neurology (2010) CC

Prevention of stroke and transient ischemic attack includes both conventional approaches to vascular risk factor management (blood pressure lowering, cholesterol reduction with statins, smoking cessation and antiplatelet therapy) and more specific interventions, such as carotid revascularization or... more

Download (10)

View PDF (9)

Access to Heart Failure Medicines in Low- and Middle-Income Countries: An Analysis of Essential Medicines Lists, Availability, Price, and Affordability

Agarwal, A.; Husain, M.J.; Datta, B. et al. Circulation: Heart Failure (2022) CC

Heart failure (HF) is a leading global public health problem with >64 million prevalent cases globally. Patients with HF with reduced ejection fraction (HFrEF) from low- and middle-income countries experience a 22% to 58% higher 1-year mortality rate than those in high-income countries.1 Guideline-d... more

Download (19)

View PDF (18)

Guidelines for the management of asthma in adults and adolescents: Position statement of the South African Thoracic Society – 2021 update

Lalloo, U.G.; Kalla, I.S.; Abdool-Gaffar, S. et al. African Journal of Thoracic and Critical Care Medicine (2021) CC

sthma prevalence is increasing worldwide, and surveys indicate that most patients in developed and developing countries, including South Africa, do not receive optimal care and are therefore not well controlled. Standard management guidelines adapted to in-country realities are important to support ... more

Download (24)

View PDF (14)

Type 2 diabetes in adults: choosing medicines

National Institute for Health and Care Excellence (2022) CC2

Factors to take into account when choosing, reviewing and changing medicines. Rescue therapy: For symptomatic hyperglycaemia, consider insulin or a sulfonylurea and review when blood glucose control has been achieved. Diet and lifestyle advice: At each point reinforce advice about diet and life... more

Download (14)

View PDF (17)

COPD Foundation Educational Materials - EPOC 201: Más allá de lo básico

COPD Foundation COPD Foundation (2022) CC2

The document provides comprehensive guidance for people with COPD, covering treatment and medication management, oxygen therapy, mucus control, exercise, smoking cessation, nutrition, associated conditions, and strategies to prevent exacerbations. It emphasizes patient education, self-management, an... more

Download (24)

View PDF (17)

COPD Foundation Educational Materials - BPCO 201 - pour aller plus loin

COPD Foundation COPD Foundation (2022) CC2

The document provides practical guidance for individuals with COPD, covering topics such as medication management, oxygen therapy, mucus control, physical exercise, smoking cessation, nutrition, associated conditions, and how to prevent and manage exacerbations. It emphasizes the importance of patie... more

Download (24)

View PDF (20)

Severe and Difficult Asthma: Diagnosis and Management—Challenges for a Low‐Resource Environment

Bush, A. Springer Link (2021) CC2

Severe and difficult asthma in a low- and middle-income country (LMIC) can relate to lack of availability of basic medications; potentially reversible factors such as poor adherence or comorbidities such as obesity inhibiting a good response to treatment; and (rarely) true severe, therapy-resistant ... more

Download (20)

View PDF (19)

Access to essential respiratory medications remains elusive in LMICs

Karmali, D.; Siddharthan, T. (2022) CC

Over 90% of the morbidity and mortality related to chronic obstructive pulmonary disease (COPD) and asthma occurs in low-income and middle-income countries (LMICs) due to well documented factors including decreased access to screening, trained health professionals, and therapies for disease manageme... more

Download (11)

View PDF (12)

Dolutegravir Resistance in Malawi’s National HIV Treatment Program

van Ossterhout, J. J.; Chipungu, C.; Nkhoma, L. et all. (2022) CC2

Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on dolutegravir-based antiretroviral therapy (November 2020– September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 ... more

Download (3)

View PDF (4)

Worldwide rates of diagnosis and effective treatment for cystic fibrosis

Guo, J.; Garratt, A.; Hill, A. Journal of Cystic Fibrosis (2022) CC

Time has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor. There is currently limited evidence regarding both the global epidemiology of CF and access to this transforma... more

Nepal: National List of Essential Medicines, 2021 recommended

Nepal: National List of Essential Medicines, 2021
recommended